[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Giagounidis AA, Hildebrandt B, Heinsch M, Germing U, Aivado M, Aul C: Acute basophilic leukemia. Eur J Haematol; 2001 Aug;67(2):72-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukemia.
  • Acute basophilic leukemia has recently been included into a revised classification of acute leukemias proposed by the WHO panel.
  • Due to the rarity of the disease, consistent diagnostic criteria are lacking.
  • We report on two cases of acute basophilic leukemia that occurred in our department during the last 10 yr.
  • Treatment of our patients consisted of supportive treatment in the one with normal karyotype and aggressive chemotherapy in the other patient.
  • Both patients died within one year after diagnosis due to progressive or recurrent leukemia.
  • [MeSH-major] Leukemia, Basophilic, Acute / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosome Aberrations. Coloring Agents. Cytarabine / administration & dosage. Cytoplasmic Granules / chemistry. Fatal Outcome. Humans. Idarubicin / administration & dosage. Immunophenotyping. Karyotyping. Leukocyte Count. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / pathology. Periodic Acid-Schiff Reaction. Peroxidase / analysis. Recurrence. Tolonium Chloride. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722593.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 15XUH0X66N / Tolonium Chloride; EC 1.11.1.7 / Peroxidase; ZRP63D75JW / Idarubicin
  •  go-up   go-down


2. Yokohama A, Tsukamoto N, Hatsumi N, Suto M, Akiba T, Uchiumi H, Maehara T, Matsushima T, Karasawa M, Murakami H, Shinonome S, Saito H, Nojima Y: Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis. Int J Hematol; 2002 Apr;75(3):309-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis.
  • De novo acute basophilic leukemia (ABL) is a rare form of myeloid leukemia.
  • The low prevalence of ABL makes it difficult to define its clinical characteristics and to establish an effective therapeutic protocol.
  • The diagnosis of ABL depended on the following:.
  • The patient achieved complete remission with intensive chemotherapy composed of idarubicin and cytosine arabinoside and was disease free during the following 30 months.
  • [MeSH-major] Antigens, CD / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Basophilic, Acute / diagnosis. Mast Cells / immunology. Receptors, Cytokine / genetics
  • [MeSH-minor] Bone Marrow / pathology. Cytarabine / administration & dosage. Diagnosis, Differential. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Receptors, IgE / blood

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2000 Feb;32(1):52-5 [10740808.001]
  • [Cites] Exp Hematol. 1993 Jan;21(1):119-25 [7678084.001]
  • [Cites] J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1177-83 [7798557.001]
  • [Cites] Br J Haematol. 1997 Jul;98(1):170-6 [9233581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2288-92 [3258425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):735-9 [7678463.001]
  • [Cites] Cytometry. 1999 Mar 1;35(3):249-59 [10082306.001]
  • [Cites] Blood. 1989 Aug 1;74(2):613-21 [2665851.001]
  • [Cites] Am J Hematol. 1989 Jul;31(3):173-80 [2787115.001]
  • [Cites] Blood. 1990 Nov 15;76(10):1956-61 [1700728.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 15;84(2):99-104 [8536230.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2333-42 [10498605.001]
  • [Cites] Eur J Clin Invest. 1995 Oct;25(10):715-20 [8557056.001]
  • [Cites] Blood. 1989 May 1;73(6):1504-12 [2653458.001]
  • [Cites] Blood. 1989 Aug 1;74(2):565-71 [2546627.001]
  • [Cites] Blood. 1999 May 15;93(10):3338-46 [10233886.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1992 Dec 15;80(12):3009-21 [1281684.001]
  • [Cites] Neoplasma. 1998;45(4):198-203 [9890661.001]
  • [Cites] Blood. 1982 Jul;60(1):38-45 [7082845.001]
  • [Cites] Immunology. 1996 Apr;87(4):535-43 [8675206.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):650-2 [7734371.001]
  • [Cites] Leuk Lymphoma. 1999 Jan;32(3-4):269-78 [10037024.001]
  • [Cites] Leuk Lymphoma. 1995;18 Suppl 1:57-60 [7496356.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2237-45 [1384799.001]
  • [Cites] Am J Clin Pathol. 1991 Aug;96(2):160-70 [1862771.001]
  • [Cites] Adv Immunol. 1992;52:333-423 [1332448.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1987 Spring;9(1):27-32 [2438957.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2343-56 [10498606.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):110-4 [7804964.001]
  • [Cites] J Allergy Clin Immunol. 2000 Dec;106(6):1190-5 [11112905.001]
  • [Cites] J Med. 1995;26(5-6):235-40 [8721900.001]
  • [Cites] J Allergy Clin Immunol. 2000 Aug;106(2):321-8 [10932077.001]
  • (PMID = 11999362.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Cytokine; 0 / Receptors, IgE; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


3. Scolyer RA, Brun M, D'Rozario J, Webb M: Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. Pathology; 2000 Feb;32(1):52-5
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood.
  • Acute basophilic leukemia is an uncommon form of acute leukemia, rarely occurring as a de novo disease.
  • We describe a case of de novo acute basophilic leukemia occurring in a 47-year-old man who presented with abnormal liver function tests in the absence of leukemic infiltration of the liver.
  • We postulate that this presentation occurred as a consequence of pathophysiological features of the malignant basophilic blast cells.
  • [MeSH-major] Leukemia, Basophilic, Acute / diagnosis. Leukemic Infiltration / pathology. Liver / pathology. Liver Function Tests. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / pathology. Cytarabine / therapeutic use. Cytoplasmic Granules / ultrastructure. Diagnosis, Differential. Drug Therapy, Combination. Fatal Outcome. Humans. Idarubicin / therapeutic use. Immunophenotyping. Karyotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10740808.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


Advertisement
4. Brink DS: Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol; 2006 Sep;13(5):256-62
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
  • Transient leukemia of Down syndrome (DS-TL), also known as transient myeloproliferative disorder of Down syndrome (DS) and transient abnormal myelopoiesis of DS, occurs in approximately 10% of DS neonates and in phenotypically normal neonates with trisomy 21 mosaicism.
  • Bone marrow characteristics of DS-TL are, likewise, variable, though (in contrast to other leukemias) the bone marrow blast differential can be lower than the peripheral blood blast differential.
  • DS-TL neonates have a approximately 15% risk of developing potentially fatal liver disease and show <10% incidence of hydrops fetalis.
  • Despite its typical transient nature, 20% to 30% of DS-TL patients develop overt (nontransient) acute leukemia, usually within 3 years and typically of the M7 phenotype (acute megakaryoblastic leukemia).
  • The pathogenesis of DS-TL (and of subsequent acute leukemia) involves mutation of GATA1 (on chromosome X), which normally encodes a transcription factor integral to normal development of erythroid, megakaryocytic, and basophilic/mast cell lines.
  • Though indications for chemotherapy in DS-TL have not been firmly established, the blasts of DS-TL are sensitive to low-dose cytosine arabinoside.
  • [MeSH-minor] GATA1 Transcription Factor / genetics. Humans. Hydrops Fetalis / etiology. Infant, Newborn. Leukemia / etiology. Liver Diseases / etiology. Mutation

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998319.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 81
  •  go-up   go-down






Advertisement